Final Overall Survival Efficacy Results of Ivosidenib for Patients with Advanced Cholangiocarcinoma with IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial

Andrew X. Zhu, Teresa Macarulla, Milind M. Javle, R. Kate Kelley, Sam J. Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. Catenacci, Mitesh J. Borad, John A. Bridgewater, William P. Harris, Adrian G. Murphy, Do Youn Oh, Jonathan R. Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Christina X. Chamberlain, Elia Aguado-FraileSung Choe, Bin Wu, Hua Liu, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Ghassan K. Abou-Alfa

Research output: Contribution to journalArticlepeer-review

Original languageEnglish (US)
Pages (from-to)1669-1677
Number of pages9
JournalJAMA Oncology
Volume7
Issue number11
DOIs
StatePublished - Nov 2021

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Final Overall Survival Efficacy Results of Ivosidenib for Patients with Advanced Cholangiocarcinoma with IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial'. Together they form a unique fingerprint.

Cite this